Lancet OncologyChen B, Hu B, Li W, et al. Transformation from NSCLC to SCLC: when did it happen? Lancet Oncol 2015;16:e309.Engelman JA, Oser MG, Niederst MJ and Sequist LV: Transformation from NSCLC to SCLC: When did it happen?‑Authors' reply. Lancet Oncol 16: e309...
The agonist selected for BDC-1001 was much less active, so the dose creeps to 12 mg/kg Q2W did not result in a DLT, but also did not result in a good clinical response. As pioneers in the field of ISAC, the failure of these two companies has left the future of ISAC in limbo....
BinbinHuWeiyingLiJianxinXueEBSCO_AspLancet OncologyChen B, Hu B, Li W, et al. Transformation from NSCLC to SCLC: when did it happen? Lancet Oncol 2015;16:e309.Chen B, Hu B, Li W and Xue J: Transformation from NSCLC to SCLC: When did it happen? Lancet Oncol 16: e309,...
Transformation from NSCLC to SCLC: when did it happen? – Authors' replydoi:10.1016/S1470-2045(15)00059-5Baoqing ChenBinbin HuWeiying LiJianxin XueElsevier LtdLancet OncologyChen B, Hu B, Li W, et al. Transformation from NSCLC to SCLC: when did it happen? Lancet Oncol 2015;16:e309....